Pharmacokinetic profile and pharmacodynamic effects of romifidine hydrochloride in the horse.

The research article discusses a study on the pharmacokinetic profile and pharmacodynamic effects of romifidine hydrochloride, an α(2)-agonist frequently used in horses. The study explores how the drug affects Thoroughbred horses post intravenous administration, revealing its pharmacokinetic parameters and how they correlate with the drug’s pharmacodynamic parameters.

Methodology

• The researchers administered romifidine hydrochloride (80 μg/kg) intravenously over two minutes to six adult Thoroughbred horses. This aimed at studying the pharmacokinetic properties of the drug, which is how the body absorbs, distributes, metabolizes, and excretes it.
• Following the administration, the researchers collected and analyzed the horses’ plasma samples using a technique called liquid chromatography-mass spectrometry, which allows the identification and quantification of chemicals in a sample. The limit of quantification was less than 0.1 ng/mL, indicating the high sensitivity of the method used.
• Next, they measured pharmacodynamic parameters and arterial blood gases for 300 minutes following the administration of romifidine. The pharmacodynamic study intended to reveal how the drug influences the body, particularly its physiological effects.
• The data gathered were then statistically analyzed via mixed-effect modeling to draw relationships and conclusions.

Results

• The researchers found that the romifidine concentration versus time curve in the plasma was best described by a two-compartmental model, which indicates how the drug distributes in the body’s ‘compartments’ or areas.
• Following romifidine administration, the average time taken for the drug’s concentration to reduce by half (terminal elimination half-life) was 138.2 minutes. The volumes in the central (Vc) and peripheral (V2) compartments of the body were 1.89 and 2.57 L/kg, respectively. This suggests that the drug tends to stay in the body for an extended period.
• The maximum plasma concentration (Cmax) of the drug was approximately 51.9 ng/mL, recorded four minutes after commencement of drug administration. Meanwhile, the systemic clearance rate of the drug (the volume of blood, from which it is entirely removed per unit time), was 32.4 mL/min/kg.
• Administration of romifidine also led to a significant decrease in both heart rate and cardiac index and an increase in mean arterial pressure, indicating an impact on the cardiovascular system.
• Furthermore, changes in both sedation scores and head heights that were different from baselines were observed for 120 minutes following administration, showing that the drug produced a prolonged sedative effect.

Conclusion

The building upon these results, the study concluded that the use of a highly sensitive analytical technique allowed a detailed description of romifidine hydrochloride’s pharmacokinetic profile. The drug was observed to have long-lasting sedative effects on horses, which correlated with the long terminal elimination half-life. This finding may guide practitioners and researchers in future drug dosage and administration decisions.